Hung-Ming Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7212902/publications.pdf

Version: 2024-02-01

70	3,190	117453	155451
papers	citations	34 h-index	55 g-index

70	70	70	3757
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Factors impacting posttraumatic growth in head-and-neck cancer patients with oncologic emergencies. Supportive Care in Cancer, 2022, 30, 4515-4525.	1.0	5
2	Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epsteinâ€“Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma. Radiotherapy and Oncology, 2022, 177, 1-8.	0.3	4
3	Association of early changes of circulating cancer stem-like cells with survival among patients with metastatic breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211101.	1.4	1
4	Combination of Epithelial Growth Factor Receptor Blockers and CDK4/6 Inhibitor for Nasopharyngeal Carcinoma Treatment. Cancers, 2021, 13, 2954.	1.7	4
5	Intensity Modulated Proton Beam Therapy versus Volumetric Modulated Arc Therapy for Patients with Nasopharyngeal Cancer: A Propensity Score-Matched Study. Cancers, 2021, 13, 3555.	1.7	15
6	Whole-exome sequencing identifies biosignatures that predict adverse survival outcomes in surgically treated patients with oral cavity squamous cell carcinoma. Oral Oncology, 2021, 122, 105547.	0.8	3
7	Circulating p16-Positive and p16-Negative Tumor Cells Serve as Independent Prognostic Indicators of Survival in Patients with Head and Neck Squamous Cell Carcinomas. Journal of Personalized Medicine, 2021, 11, 1156.	1.1	2
8	Pretreatment 18F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma. Oral Oncology, 2020, 104, 104628.	0.8	10
9	Prognostic impact of extratumoral perineural invasion in patients with oral cavity squamous cell carcinoma. Cancer Medicine, 2019, 8, 6185-6194.	1.3	20
10	Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head and Neck, 2019, 41, 19-45.	0.9	70
11	Amplification of the EGFR and CCND1 Are Coordinated and Play Important Roles in the Progression of Oral Squamous Cell Carcinomas. Cancers, 2019, 11, 760.	1.7	28
12	The Integration of a Three-Dimensional Spheroid Cell Culture Operation in a Circulating Tumor Cell (CTC) Isolation and Purification Process: A Preliminary Study of the Clinical Significance and Prognostic Role of the CTCs Isolated from the Blood Samples of Head and Neck Cancer Patients. Cancers, 2019, 11, 783.	1.7	14
13	The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing. Cancers, 2019, 11, 540.	1.7	12
14	Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. BMC Cancer, 2019, 19, 1167.	1.1	20
15	Optically-induced-dielectrophoresis (ODEP)-based cell manipulation in a microfluidic system for high-purity isolation of integral circulating tumor cell (CTC) clusters based on their size characteristics. Sensors and Actuators B: Chemical, 2018, 258, 1161-1173.	4.0	62
16	An Optically Induced Dielectrophoresis (ODEP)-Based Microfluidic System for the Isolation of High-Purity CD45neg/EpCAMneg Cells from the Blood Samples of Cancer Patientsâ€”Demonstration and Initial Exploration of the Clinical Significance of These Cells. Micromachines, 2018, 9, 563.	1.4	35
17	Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 233.	3.5	23
18	A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. Biomedical Journal, 2018, 41, 129-136.	1.4	23

#	Article	IF	Citations
19	Roles of preoperative C-reactive protein are more relevant in buccal cancer than other subsites. World Journal of Surgical Oncology, 2017, 15, 47.	0.8	19
20	Isolation of label-free and viable circulating tumour cells (CTCs) from blood samples of cancer patients through a two-step process: negative selection-type immunomagnetic beads and spheroid cell culture-based cell isolation. RSC Advances, 2017, 7, 29339-29349.	1.7	18
21	Progesterone analogues reduce plasma Epsteinâ€“Barr virus DNA load and improve pain control in recurrent/metastatic nasopharyngeal carcinoma patients under supportive care. Biomedical Journal, 2017, 40, 212-218.	1.4	6
22	The utilization of optically-induced-dielectrophoresis (ODEP)-based virtual cell filters in a microfluidic system for continuous isolation and purification of circulating tumour cells (CTCs) based on their size characteristics. Sensors and Actuators B: Chemical, 2017, 241, 245-254.	4.0	69
23	Predictive value of 1H MR spectroscopy and 18F-FDG PET/CT for local control of advanced oropharyngeal and hypopharyngeal squamous cell carcinoma receiving chemoradiotherapy: a prospective study. Oncotarget, 2017, 8, 115513-115525.	0.8	2
24	Impact of Palliative Care Consultation Service on Terminally Ill Cancer Patients. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	15
25	Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. Scientific Reports, 2016, 6, 31423.	1.6	34
26	Dynamic contrast-enhanced MRI, diffusion-weighted MRI and 18F-FDG PET/CT for the prediction of survival in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiation. European Radiology, 2016, 26, 4162-4172.	2.3	55
27	Application of optically-induced-dielectrophoresis in microfluidic system for purification of circulating tumour cells for gene expression analysis- Cancer cell line model. Scientific Reports, 2016, 6, 32851.	1.6	79
28	Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget, 2016, 7, 53217-53229.	0.8	9
29	Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma. World Journal of Surgical Oncology, 2015, 13, 253.	0.8	28
30	Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial. Japanese Journal of Clinical Oncology, 2015, 45, 819-827.	0.6	19
31	Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 1448-1455.	0.9	55
32	Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma. Oncotarget, 2015, 6, 31323-31334.	0.8	16
33	Using SCC Antigen and CRP Levels as Prognostic Biomarkers in Recurrent Oral Cavity Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e103265.	1.1	29
34	Clinical Utility of Multimodality Imaging with Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and 18F-FDG PET/CT for the Prediction of Neck Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiation. PLoS ONE, 2014, 9, e115933.	1.1	53
35	Predictive Factors For Do-Not-Resuscitate Designation Among Terminally Ill Cancer Patients Receiving Care From a Palliative Care Consultation Service. Journal of Pain and Symptom Management, 2014, 47, 271-282.	0.6	31
36	Impact of palliative care consultative service on disease awareness for patients with terminal cancer. Supportive Care in Cancer, 2013, 21, 1973-1981.	1.0	25

#	Article	IF	Citations
37	Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Annals of Nuclear Medicine, 2013, 27, 710-719.	1.2	18
38	Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. Oral Oncology, 2013, 49, 620-625.	0.8	42
39	A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clinica Chimica Acta, 2013, 419, 77-84.	0.5	43
40	The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncology, 2013, 49, 71-78.	0.8	41
41	Refining the role of preoperative Câ€reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope, 2013, 123, 2690-2699.	1.1	72
42	Dynamic Contrast-Enhanced MR Imaging Predicts Local Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiotherapy. PLoS ONE, 2013, 8, e72230.	1.1	49
43	Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma. Biomedical Journal, 2013, 36, 229.	1.4	10
44	Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels. Annals of Surgical Oncology, 2012, 19, 3856-3864.	0.7	57
45	Prognostic Significance of ¹⁸F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma. Journal of Nuclear Medicine, 2012, 53, 21-28.	2.8	96
46	Plasma epsteinâ€barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. Head and Neck, 2012, 34, 1064-1070.	0.9	57
47	Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncology, 2012, 48, 67-72.	0.8	39
48	Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World Journal of Surgical Oncology, 2012, 10, 40.	0.8	60
49	Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma. Nuclear Medicine Communications, 2011, 32, 989-996.	0.5	64
50	Clinical significance of preoperative squamous cell carcinoma antigen in oralâ€cavity squamous cell carcinoma. Laryngoscope, 2011, 121, 971-977.	1.1	35
51	Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewingâ€prevalent area. Head and Neck, 2011, 33, 1758-1764.	0.9	19
52	Comprehensive imaging of residual/recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. European Radiology, 2010, 20, 2229-2240.	2.3	79
53	Influence of Pathological Nodal Status and Maximal Standardized Uptake Value of the Primary Tumor and Regional Lymph Nodes on Treatment Plans in Patients With Advanced Oral Cavity Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2010, 77, 421-429.	0.4	28
54	Proteomics of the Radioresistant Phenotype in Head-and-Neck Cancer: Gp96 as a Novel Prediction Marker and Sensitizing Target for Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 246-256.	0.4	48

#	Article	IF	Citations
55	Quality of Endâ€ofâ€Life Care Between Medical Oncologists and Other Physician Specialists for Taiwanese Cancer Decedents, 2001â€“2006. Oncologist, 2009, 14, 1232-1241.	1.9	21
56	Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: The role of standardized uptake value. Oral Oncology, 2009, 45, 52-58.	0.8	52
57	EGFR protein overexpression and mutation in areca quidâ€“associated oral cavity squamous cell carcinoma in Taiwan. Head and Neck, 2009, 31, 1068-1077.	0.9	28
58	Pretreatment Primary Tumor SUVmax Measured by FDG-PET and Pathologic Tumor Depth Predict for Poor Outcomes in Patients With Oral Cavity Squamous Cell Carcinoma and Pathologically Positive Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2009, 73, 764-771.	0.4	78
59	Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. European Radiology, 2009, 19, 2965-2976.	2.3	38
60	Neck treatment of patients with early stage oral tongue cancer. Cancer, 2008, 112, 1066-1075.	2.0	120
61	Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Science, 2008, 99, 1507-1514.	1.7	264
62	Analysis of Risk Factors of Predictive Local Tumor Control in Oral Cavity Cancer. Annals of Surgical Oncology, 2008, 15, 915-922.	0.7	239
63	18F-FDG PET Can Replace Conventional Work-up in Primary M Staging of Nonkeratinizing Nasopharyngeal Carcinoma. Journal of Nuclear Medicine, 2007, 48, 1614-1619.	2.8	93
64	Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1032-1040.	3.3	60
65	[18F]Fluorodeoxyglucose Positron Emission Tomography Is More Sensitive Than Skeletal Scintigraphy for Detecting Bone Metastasis in Endemic Nasopharyngeal Carcinoma at Initial Staging. Journal of Clinical Oncology, 2006, 24, 599-604.	0.8	95
66	Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. Journal of Nuclear Medicine, 2006, 47, 1447-54.	2.8	21
67	Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. International Journal of Radiation Oncology Biology Physics, 2005, 62, 501-507.	0.4	96
68	Nodal metastases of nasopharyngeal carcinoma: patterns of disease on MRI and FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 1073-80.	3.3	146
69	Clinical usefulness of 18F-FDG PET in nasopharyngeal carcinoma patients with questionable MRI findings for recurrence. Journal of Nuclear Medicine, 2004, 45, 1669-76.	2.8	49
70	The XRCC1 399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 439-43.	1.1	20